<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="81977">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038140</url>
  </required_header>
  <id_info>
    <org_study_id>CSU2011-07E</org_study_id>
    <nct_id>NCT02038140</nct_id>
  </id_info>
  <brief_title>Zimmer Trabecular Metal Total Ankle</brief_title>
  <official_title>Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to obtain implant survivorship and clinical outcome
      data for commercially available Zimmer Trabecular Metal Total Ankle implants used in primary
      or revision total ankle arthroplasty. The assessment will include implant survivorship and
      clinical performance measured by pain and function, quality of life data, radiographic
      parameters and survivorship.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a prospective, multicenter, study of the commercially available Zimmer
      Trabecular Metal Ankle semiconstrained implants. The study will require each site to obtain
      Institutional Review Board approval prior to study enrollment. All potential study subjects
      will be required to participate in the Informed Consent Process.

      All study subjects will undergo preoperative clinical evaluations prior to their primary or
      revision total ankle arthroplasty. The post-operative clinical and radiographic evaluations
      will be conducted at 6 weeks, 6 month, 1 year, 2, 3, 5, 7, and 10 years. Follow-up surveys
      will occur at 4, 6, 8, and 9 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survivorship</measure>
    <time_frame>10 years</time_frame>
    <description>Survival of the implants after 10 years which is based on removal of the prosthesis and will be determined using the Kaplan Meier Method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American Orthopaedic Foot and Ankle Society Score</measure>
    <time_frame>First 2 years</time_frame>
    <description>Performance os the Zimmer Trabecular Metal Ankle after 2 years which is assessed by the AOFAS score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Degenerative Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Post Traumatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Zimmer TM Total Ankle System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zimmer Trabecular Metal Total Ankle System</intervention_name>
    <description>Primary or revision total ankle replacement</description>
    <arm_group_label>Zimmer TM Total Ankle System</arm_group_label>
    <other_name>Primary Ankle Replacement</other_name>
    <other_name>Total Ankle Arthroplasty</other_name>
    <other_name>Total Ankle Replacement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is &gt; 18 years of age

          -  The patient is skeletally mature

          -  The patient qualifies for primary or revision total ankle replacement based on
             physical exam and medical history including the following: degenerative arthritis,
             rheumatoid arthritis, post-traumatic arthritis.

          -  The patient is willing and able to provide written informed consent

          -  Patient is willing and able to cooperate in the required post-operative therapy

          -  The patient is willing and able to complete scheduled follow-up evaluations
             questionnaires as described in the Informed Consent

          -  The patient has participated in the Informed Consent process and has signed the
             Institutional Review Board/European Commission approved Informed Consent

        Exclusion Criteria:

          -  The patient is: a prisoner, mentally incompetent or unable to understand what
             participation in the study entails, a known alcohol or drug abuser, anticipated to be
             non-compliant.

          -  The patient has one of the following compromising the affected limb: ankle
             arthrodesis with malleolar exeresis, severe neurological or vascular disease, loss of
             musculature or neuromuscular compromise, severe instability, maltracking or
             misalignment of the tibia and talus uncorrectable by surgery.

          -  The patient has a local/systemic infection that may affect the prosthetic joint

          -  The patient has a previous history of infection in the affected joint

          -  The patient is known to be pregnant

          -  The patient has insufficient bone stock or bone quality to fix the components (i.e.
             osteoporosis, Charcot's disease)

          -  The patient has a known sensitivity or allergic reaction to one or more of the
             implanted materials

          -  The patient is unwilling or unable to give consent or to comply with the follow-up
             program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryan Boylan, BS</last_name>
    <phone>574-371-9784</phone>
    <email>ryan.boylan@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeff Schram, BS, MS, MA</last_name>
    <phone>574-371-9786</phone>
    <email>jeffrey.schram@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caren Galloway, CRA</last_name>
      <phone>916-734-6999</phone>
      <email>Caren.galloway@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Giza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Associates of Grand Rapids REI</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Padley</last_name>
      <email>Michelle.Padley@oamichigan.com</email>
    </contact>
    <investigator>
      <last_name>John Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Research Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Prassas</last_name>
      <email>katherine.prassas@orthocarolina.com</email>
    </contact>
    <investigator>
      <last_name>John Ellington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705-4677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Friend</last_name>
      <email>Jennifer.friend@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Selene Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UBC Providence Health Care Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biraj Bora, MS</last_name>
      <phone>604-806-8743</phone>
      <email>bbora@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Biraj Bora, MS</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kevin Wing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alastair Younger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital Finland</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannu Tiusanen, MD</last_name>
      <email>hannu.tiusanen@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Ortopedico Galeazzi</name>
      <address>
        <city>Milan</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Federico Usuelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital-Stiftung Universitatsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabian Krause, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 25, 2016</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Ankle Replacement</keyword>
  <keyword>Total Ankle Arthroplasty</keyword>
  <keyword>Total Ankle Replacement</keyword>
  <keyword>Trabecular Metal Total Ankle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
